There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Tandem Diabetes Care (TNDM) and Cormedix (CRMD) with bullish sentiments.
Tandem Diabetes Care (TNDM)
Oppenheimer analyst Steven Lichtman maintained a Buy rating on Tandem Diabetes Care today and set a price target of $130.00. The company’s shares closed last Tuesday at $84.98.
According to TipRanks.com, Lichtman is a 5-star analyst with an average return of 16.6% and a 57.8% success rate. Lichtman covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Merit Medical Systems, and Integra Lifesciences.
Currently, the analyst consensus on Tandem Diabetes Care is a Moderate Buy with an average price target of $131.17, a 62.8% upside from current levels. In a report issued on March 22, Piper Sandler also reiterated a Buy rating on the stock with a $132.00 price target.
See today’s analyst top recommended stocks >>
Needham analyst Chad Messer assigned a Buy rating to Cormedix today and set a price target of $31.00. The company’s shares closed last Tuesday at $8.99.
According to TipRanks.com, Messer is a 4-star analyst with an average return of 6.9% and a 44.1% success rate. Messer covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals, Aeglea Biotherapeutics, and Ionis Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cormedix with a $19.38 average price target, implying a 123.5% upside from current levels. In a report released today, JMP Securities also maintained a Buy rating on the stock with a $23.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.